Business
Adagio Medical FULCRUM-VT U.S. Pivotal Study Acute Results to be Presented in Late-Breaking Session at VT Symposium
LAGUNA HILLS, Calif., September 18, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that acute results from the Company’s FULCRUM-VT U.S. pivotal study have been accepted for presentation in a late-breaking clinical science session at The 20th Annual International Symposium on Ventricular Arrhythmias, being held from October 10- 11, 2025 at the Philadelp
About this update from Adagio Medical Holdings, Inc
[{"type":"text","content":"LAGUNA HILLS, Calif., September 18, 2025--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that acute results from the Company’s FULCRUM-VT U.S. pivotal study have been accepted for presentation in a late-breaking clinical science session at The 20th Annual International Symposium on Ventricular Arrhythmias, being held from October 10- 11, 2025 at the Philadelphia Marriott Downtown. The Investigational Device Exemption ("IDE") study is the first study powered to evaluate the safety and effectiveness of Ultralow Temperature Cryoablation ("ULTC") for the treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT) in patients with both ischemic and nonischemic cardiomyopathy.","length":881,"tagName":"p"},{"type":"text","content":""We are delighted that the FULCRUM-VT acute data will be featured as part of a late-breaking session at VT Symposium," said Todd Usen, Chief Executive Officer of Adagio Medical. "On behalf of the entire Adagio Medical team, I want to thank all of the investigators, research coordinators and patients who have supported this study and whose commitment to serving this underserved population of patients will bring us one step closer to a purpose-built solution for VT. We thank the VT Symposium for this opportunity, and we look forward to the results being shared in Philadelphia."","length":602,"tagName":"p"},{"type":"text","content":"Adagio Medical’s ULTC technology will be featured in the following presentations during the VT Symposium:","length":105,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"2","rowspan":"1","val":[{"type":"text","content":"Friday October 10, 2025","length":23,"tagName":"p"}]}]},{"val":[{"colspan":"2","rowspan":"1","val":[{"type":"text","content":"SESSION VI: Late Breaking + New/Ongoing Trial Results/Information","length":65,"tagName":"p"}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"width:15%;","val":[{"type":"text","content":"Presentation Title:","length":19,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"vertical-align:top;padding-left:0.0px;width:85%;","val":[{"type":"text","content":"Ultralow Temperature Cryoabla...